key: cord-0056222-ixm28zbn
authors: Edroso Jarne, Paloma Eugenia; Lozano Gómez, Herminia; Abansés Moreno, Paula
title: Transfusion reaction to hyperimmune plasma in patients with severe COVID-19 infection()
date: 2021-02-11
journal: Med Clin (Engl Ed)
DOI: 10.1016/j.medcle.2020.11.011
sha: 2e46647c8a90dc5ad258685404656ed408bb4bc4
doc_id: 56222
cord_uid: ixm28zbn

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Letter to the Editor To the Editor:

Following the first wave of COVID-19 infections in spring 2020, treatment optimization studies did not provide conclusive evidence of clinical efficacy in patients with severe pneumonia 1 . Since mid-June, numerous outbreaks of the SARS-CoV-2 disease have hit some areas of Spain. In Aragon, infections continue to increase and account for 33% of COVID-19 hospitalizations throughout the country 2 . Currently there is still no vaccine available and the interest in achieving passive immunization in the population has placed convalescent plasma and hyperimmune globulin as valid options when it comes to achieving this goal 3 . Convalescent or hyperimmune plasma is extracted from patients infected by COVID-19 who have overcome the disease and have generated antibodies in sufficient titers against this pathogen which, when infused into the recipient, promote binding with the virus and facilitate its phagocytosis. Hyperimmune plasma transfusion allows for faster immunization in infected individuals and thus shorten the disease or reduce its symptoms, so it should be administered in the first days of progression 3 . Like all other blood products, hyperimmune plasma can be responsible for transfusion reactions, including allergic and anaphylactic reactions, haemolysis, circulatory overload, and transfusion-related acute lung injuries. Based on published data, the incidence of serious adverse reactions to date is low (<░1%) 4 .

We report the case of two young male patients admitted to the intensive care unit (ICU) for severe bilateral pneumonia after COVID-19 infection who had a transfusion reaction after the administration of hyperimmune plasma against COVID-19.

48-year-old male from Colombia with symptoms compatible with COVID-19 infection and positive PCR. He went to the emergency department due to respiratory distress and was admitted to the ward, where he developed respiratory deterioration, for which he was transferred to the ICU. Treatment was initially started with remdesivir 200░mg and then 100░mg every 24░h and dexamethasone 20░mg every 24░h. Two bags of hyperimmune plasma were administered, after which he presented an urticarial reaction on the face and trunk along with increased dyspnoea and desaturation, requiring an increase in oxygen concentration and flow. Treatment with dexchlorpheniramine 5░mg every 8░h was started and the lesions disappeared after 24░h. The patient showed good subsequent progression, high-flow oxygen therapy (HFOT) was withdrawn, and he was discharged to the ward.

Case 2. 45-year-old male from Cameroon. He went to the emergency department due to clinical worsening in the context of SARS-CoV-2 infection. He was admitted to the ward, where he showed a poor progression requiring admission to the ICU. Treatment started with HFOT and dexamethasone 20░mg every 24░h, remdesivir (200░mg load dose and 100░mg every 24░h later) and hyperimmune plasma, developing itchy hives in the body that subsided with 10░mg of IV dexchlorpheniramine. The course was favourable, and he was discharged.

Uso de plasma de convalecientes para tratamiento de COVID-19 Historia y evidencia

Transfusión de plasma convaleciente de pacientes con COVID-19: Propuesta de la Sociedad Peruana de Inmunología y la Asociación Médica Peruana de Patología Clínica para su implementación en nuestro país

Coronavirus disease 2019 (COVID-19): Convalescent plasma and hyperimmuneglobulin

Safety Update: COVID-19 Convalescent Plasma in 20,000 HospitalizedPatients